Overview

Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

Status:
Completed

Trial end date:
2010-05-20

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Prochymal™ versus placebo in combination with corticosteroids as initial therapy for acute GVHD. Corticosteroids have been the primary therapy for patients with previously untreated acute GVHD and the historical published data define an expected 35% complete response (CR) at Day +28 using this therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Mesoblast International Sàrl
Mesoblast, Inc.

Treatments:

Remestemcel-l